Jazz Pharmaceuticals announces executive changes

PALO ALTO, Calif. A specialty pharmaceutical company focused on drugs for neurological and psychiatric conditions has made changes to its management and board of directors.

Jazz Pharmaceuticals announced Thursday that CEO and board member Samuel Saks had resigned from both positions, effective Friday. Saks will serve as a consultant to the company on medical and clinical matters.

The company has appointed Bruce Cozadd to the position of CEO and Robert Myers to the board position. Cozadd was previously executive chairman since the company’s founding, in 2003, and worked at ALZA Corp. from 1991 to 2001. Myers was the company’s EVP and chief business officer from the company’s founding to 2007, when he took the position of president.

“We thank Sam for his enormous contributions to Jazz Pharmaceuticals since its founding in 2003,” Cozadd said. “His dedication to patients, employees and our company culture has been an inspiration to all of us.”